Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Baxter
Mallinckrodt
Deloitte
Johnson and Johnson
Covington
Harvard Business School
McKesson
Queensland Health

Generated: May 27, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,993,567

« Back to Dashboard

Title:Cyclic protein tyrosine kinase inhibitors
Abstract: Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.
Inventor(s): Das; Jagabandhu (Mercerville, NJ), Padmanabha; Ramesh (Hamden, CT), Chen; Ping (Franklin Park, NJ), Norris; Derek (Pennington, NJ), Doweyko; Arthur M. P. (Long Valley, NJ), Barrish; Joel C. (Richboro, PA), Wityak; John (Carlsbad, CA)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Filing Date:Mar 27, 2014
Application Number:14/226,868
Claims:1. A compound of formula I or salt thereof ##STR00640## where Q is thiazole optionally substituted with R.sub.1; Z is a single bond; X.sub.1 and X.sub.2 together form .dbd.O; R.sub.1 is (1) hydrogen or R.sub.6, where R.sub.6 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclo, or heterocycloalkyl, each of which is unsubstituted or substituted with Z.sub.1, Z.sub.2 and one or more groups Z.sub.3; q is 1 or 2; R.sub.2 is hydrogen, R.sub.6, --Z.sub.4--R.sub.6 or --Z.sub.13--NR.sub.7R.sub.8; R.sub.3 is --Z.sub.13--NR.sub.7R.sub.8 where Z.sub.13 is --C(O)--; R.sub.4 and R.sub.5 (1) are each independently hydrogen or R.sub.6; (2) --Z.sub.4--N(R.sub.9)--Z.sub.5--NR.sub.10R.sub.11; (3) --N(R.sub.9)Z.sub.4R.sub.6; or R.sub.7 is alkyl; R.sub.8, R.sub.9, R.sub.10, R.sub.11 and R.sub.12 (1) are each independently hydrogen or R.sub.6; R.sub.13 is (1) cyano; (2) nitro; (3) --NH.sub.2; (4) --NHOalkyl; (5) --OH; (6) --NHOaryl; (7) --NHCOOalkyl; (8) --NHCOOaryl; (9) --NHSO.sub.2alkyl; (10) --NHSO.sub.2aryl; (11) aryl; (12) heteroaryl; (13) --Oalkyl; or (14) --Oaryl; R.sub.14 is (1) --NO.sub.2; (2) --COOalkyl; or (3) --COOaryl; Z.sub.1, Z.sub.2 and Z.sub.3 are each independently (1) hydrogen or Z.sub.6, where Z.sub.6 is (i) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, alkylaryl, cycloalkylaryl, heterocyclo, or heterocycloalkyl; (ii) a group (i) which is itself substituted by one or more of the same or different groups (i); or (iii) a group (i) or (ii) which is substituted by one or more of the following groups (2) to (16) of the definition of Z.sub.1, Z.sub.2 and Z.sub.3; (2) --OH or --OZ.sub.6; (3) --SH or --SZ.sub.6; (4) --C(O).sub.qH, --C(O).sub.qZ.sub.6, or --O--C(O).sub.qZ.sub.6; (5) --SO.sub.3H, --S(O).sub.qZ.sub.6; or S(O).sub.qN(Z.sub.9)Z.sub.6; (6) halo; (7) cyano; (8) nitro; (9) --Z.sub.4--NZ.sub.7Z.sub.8; (10) --Z.sub.4--N(Z.sub.9)--Z.sub.5--NZ.sub.7Z.sub.8; (11) --Z.sub.4--N(Z.sub.10)--Z.sub.5--Z.sub.6; (12) --Z.sub.4--N(Z.sub.10)--Z.sub.5--H; (13) oxo; or (14) --O--C(O)--Z.sub.6; Z.sub.4 and Z.sub.5 are each independently (1) a single bond; (2) --Z.sub.11--S(O).sub.q--Z.sub.12--; (3) --Z.sub.11--C(O)--Z.sub.12--; (4) --Z.sub.11--C(S)--Z.sub.12--; (5) --Z.sub.11--O--Z.sub.12--; (6) --Z.sub.11--S--Z.sub.12--; (7) --Z.sub.11--O--C(O)--Z.sub.12--; or (8) --Z.sub.11--C(O)--O--Z.sub.12--; Z.sub.7, Z.sub.8, Z.sub.9 and Z.sub.10 (1) are each independently hydrogen or Z.sub.6; Z.sub.11 and Z.sub.12 are each independently (1) a single bond; (2) alkylene; (3) alkenylene; or (4) alkynylene; and Z.sub.13 is (1) a single bond; (2) --Z.sub.11--S(O).sub.qZ.sub.12--; (3) --Z.sub.11--C(O)--Z.sub.12--; (4) --Z.sub.11--C(S)--Z.sub.12--; (5) --Z.sub.11--O--Z.sub.12--; (6) --Z.sub.11--S--Z.sub.12--; (7) --Z.sub.11--O--C(O)--Z.sub.12--; (8) --Z.sub.11--C(O)--O--Z.sub.12--; (9) --C(NR.sub.13)--; (10) --C(CHR.sub.14)--; or (11) --C(C(R.sub.14).sub.2)-- provided said compound is other than a compound of formula (ix) ##STR00641## where R.sub.2i is hydrogen or alkyl; R.sub.3i is --C(O)--NH-(alk); and R.sub.58 and R.sub.59 are independently hydrogen, alkyl or halogen.

2. A compound of claim 1 wherein R.sub.1 is hydrogen, alkyl, or aryl.

3. A compound of claim 2 wherein R.sub.1 is hydrogen.

4. A compound of claim 2 wherein R.sub.2 is hydrogen.

5. A compound of claim 2 wherein R.sub.4 is hydrogen.

6. A compound of claim 2 wherein R.sub.5 is an aryl group which is substituted with Z.sub.1, Z.sub.2 and one or more groups Z.sub.3.

7. A compound of claim 2 wherein R.sub.1 is hydrogen or alkyl, R.sub.2 and R.sub.4 are independently hydrogen or alkyl, and R.sub.5 is aryl which is unsubstituted or substituted with Z.sub.1, Z.sub.2 and one or more groups Z.sub.3.

8. A compound of claim 7 wherein R.sub.5 is aryl which is unsubstituted or independently substituted with one or more alkyl or halo.

9. A pharmaceutical composition, comprising a pharmaceutically acceptable vehicle or diluent and at least one compound of claim 1.

10. A compound of formula II or salt thereof ##STR00642## where n is 1; X.sub.3 is oxygen; A is nitrogen; B is sulfur; R.sub.1 is (1) hydrogen or R.sub.6, where R.sub.6 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclo, or heterocycloalkyl, each of which is unsubstituted or substituted with Z.sub.1, Z.sub.2 and one or more groups Z.sub.3; q is 1 or 2; R.sub.2 is hydrogen, R.sub.6, --Z.sub.4--R.sub.6 or --Z.sub.13--NR.sub.7R.sub.8; R.sub.3 is R.sub.3 is --Z.sub.13--NR.sub.7R.sub.8 where Z.sub.13 is --C(O)--; R.sub.4 and R.sub.5 (1) are each independently hydrogen or R.sub.6; (2) --Z.sub.4--N(R.sub.9)--Z.sub.5--NR.sub.10R.sub.11; (3) --N(R.sub.9)Z.sub.4R.sub.6; or R.sub.7 is alkyl; R.sub.8, R.sub.9, R.sub.10, R.sub.11 and R.sub.12 (1) are each independently hydrogen or R.sub.6; R.sub.13 is (1) cyano; (2) nitro; (3) --NH.sub.2; (4) --NHOalkyl; (5) --OH; (6) --NHOaryl; (7) --NHCOOalkyl; (8) --NHCOOaryl; (9) --NHSO.sub.2alkyl; (10) --NHSO.sub.2aryl; (11) aryl; (12) heteroaryl; (13) --Oalkyl; or (14) --Oaryl; R.sub.14 is (1) --NO.sub.2; (2) --COOalkyl; or (3) --COOaryl; Z.sub.1, Z.sub.2 and Z.sub.3 are each independently (1) hydrogen or Z.sub.6, where Z.sub.6 is (i) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, alkylaryl, cycloalkylaryl, heterocyclo, or heterocycloalkyl; (ii) a group (i) which is itself substituted by one or more of the same or different groups (i); or (iii) a group (i) or (ii) which is substituted by one or more of the following groups (2) to (16) of the definition of Z.sub.1, Z.sub.2 and Z.sub.3; (2) --OH or --OZ.sub.6; (3) --SH or --SZ.sub.6; (4) --C(O).sub.qH, --C(O).sub.qZ.sub.6, or --O--C(O).sub.qZ.sub.6; (5) --SO.sub.3H, --S(O).sub.qZ.sub.6; or S(O).sub.qN(Z.sub.9)Z.sub.6; (6) halo; (7) cyano; (8) nitro; (9) --Z.sub.4--NZ.sub.7Z.sub.8; (10) --Z.sub.4--N(Z.sub.9)--Z.sub.5--NZ.sub.7Z.sub.8; (11) --Z.sub.4--N(Z.sub.10)--Z.sub.5--Z.sub.6; (12) --Z.sub.4--N(Z.sub.10)--Z.sub.5--H; (14) --O--C(O)--Z.sub.6; Z.sub.4 and Z.sub.5 are each independently (1) a single bond; (2) --Z.sub.11--S(O).sub.q--Z.sub.12--; (3) --Z.sub.11--C(O)--Z.sub.12--; (4) --Z.sub.11--C(S)--Z.sub.12--; (5) --Z.sub.11--O--Z.sub.12--; (6) --Z.sub.11--S--Z.sub.12--; (7) --Z.sub.11--O--C(O)--Z.sub.12--; or (8) --Z.sub.11--C(O)--O--Z.sub.12--; Z.sub.7, Z.sub.8, Z.sub.9 and Z.sub.10 (1) are each independently hydrogen or Z.sub.6; Z.sub.11 and Z.sub.12 are each independently (1) a single bond; (2) alkylene; (3) alkenylene; or (4) alkynylene; and Z.sub.13 is (1) a single bond; (2) --Z.sub.11--S(O).sub.q--Z.sub.12--; (3) --Z.sub.11--C(O)--Z.sub.12--; (4) --Z.sub.11--C(S)--Z.sub.12--; (5) --Z.sub.11--O--Z.sub.12--; (6) --Z.sub.11--S--Z.sub.12--; (7) --Z.sub.11--O--C(O)--Z.sub.12--; (8) --Z.sub.11--C(O)--O--Z.sub.12--; (9) --C(NR.sub.13)--; (10) --C(CHR.sub.14)--; or (11) --C(C(R.sub.14).sub.2)--; provided said compound is other than a compound of formula (ix) ##STR00643## where R.sub.2i is hydrogen or alkyl; R.sub.3i is --C(O)--NH-(alk); and R.sub.58 and R.sub.59 are independently hydrogen, alkyl or halogen.

11. A compound of claim 10 wherein R.sub.1 is hydrogen or alkyl, R.sub.2 and R.sub.4 are independently hydrogen or alkyl, and R.sub.5 is aryl which is unsubstituted or substituted with Z.sub.1, Z.sub.2 and one or more groups Z.sub.3.

12. A compound of claim 11 wherein R.sub.5 is aryl which is unsubstituted or independently substituted with one or more alkyl or halo.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Fuji
Moodys
Cerilliant
McKesson
Dow
Medtronic
Fish and Richardson
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.